🇺🇸 ISIS 3521 in United States

20 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 3 reports (15%)
  2. Haemoglobin Decreased — 3 reports (15%)
  3. Abdominal Pain — 2 reports (10%)
  4. Lobar Pneumonia — 2 reports (10%)
  5. Platelet Count Decreased — 2 reports (10%)
  6. Pneumonia — 2 reports (10%)
  7. Shock — 2 reports (10%)
  8. Troponin T Increased — 2 reports (10%)
  9. Acute Coronary Syndrome — 1 report (5%)
  10. Angina Unstable — 1 report (5%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is ISIS 3521 approved in United States?

ISIS 3521 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ISIS 3521 in United States?

European Organisation for Research and Treatment of Cancer - EORTC is the originator. The local marketing authorisation holder may differ — check the official source linked above.